Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duncan Purtill

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Pathology|December 9, 2023
Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosisPortia Smallbone, Alison Louw, Duncan Purtill
Open Forum Infectious Diseases|February 8, 2021
<i>Mycobacterium abscessus</i> Gastric Band Infection Complicated by Immune Reconstitution Inflammatory Syndrome and Cured in the Context of Allogeneic Hematopoietic Stem Cell TransplantationNoralfazita An, Duncan Purtill, Peter Boan
Best Practice & Research. Clinical Haematology|September 15, 2010
Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?Roel Willemze, Annalisa Ruggeri, Duncan Purtill, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 7, 2022
QuantiFERON-cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantationGrace Thompson, Peter Boan, Duncan Purtill, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 12, 2021
High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipientsStephanie Lam, Peter Boan, Paola Polistena, et al.
International Journal of Hematology|December 21, 2011
Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 studyRichard Herrmann, Marian Sturm, Kathryn Shaw, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 17, 2024
Safety of intramuscular tixagevimab-cilgavimab (Evusheld<sup>®</sup>) administration in patients at risk of iatrogenic haematoma due to haematological disordersJacques A J Malherbe, Jeanie Misko, Nishani K Jayawardena, et al.
Best Practice & Research. Clinical Haematology|September 15, 2010
Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseasesVanderson Rocha, Alessandro Crotta, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2020
Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of TransplantationDavid Kliman, Ian Nivison-Smith, David Gottlieb, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 7, 2023
Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantationRaena Kaur, Duncan Purtill, Julian Cooney, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Pathology|December 9, 2023
Laboratory methods of monitoring disease response after allogeneic haematopoietic stem cell transplantation for myelofibrosisPortia Smallbone, Alison Louw, Duncan Purtill
Open Forum Infectious Diseases|February 8, 2021
<i>Mycobacterium abscessus</i> Gastric Band Infection Complicated by Immune Reconstitution Inflammatory Syndrome and Cured in the Context of Allogeneic Hematopoietic Stem Cell TransplantationNoralfazita An, Duncan Purtill, Peter Boan
Best Practice & Research. Clinical Haematology|September 15, 2010
Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?Roel Willemze, Annalisa Ruggeri, Duncan Purtill, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|January 7, 2022
QuantiFERON-cytomegalovirus to predict clinically significant cytomegalovirus infection after allogeneic hematopoietic stem cell transplantationGrace Thompson, Peter Boan, Duncan Purtill, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|May 12, 2021
High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipientsStephanie Lam, Peter Boan, Paola Polistena, et al.
International Journal of Hematology|December 21, 2011
Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 studyRichard Herrmann, Marian Sturm, Kathryn Shaw, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 17, 2024
Safety of intramuscular tixagevimab-cilgavimab (Evusheld<sup>®</sup>) administration in patients at risk of iatrogenic haematoma due to haematological disordersJacques A J Malherbe, Jeanie Misko, Nishani K Jayawardena, et al.
Best Practice & Research. Clinical Haematology|September 15, 2010
Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseasesVanderson Rocha, Alessandro Crotta, Annalisa Ruggeri, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2020
Hematopoietic Stem Cell Transplant Recipients Surviving at Least 2 Years from Transplant Have Survival Rates Approaching Population Levels in the Modern Era of TransplantationDavid Kliman, Ian Nivison-Smith, David Gottlieb, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|September 7, 2023
Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantationRaena Kaur, Duncan Purtill, Julian Cooney, et al.
Pageof 6